CD8A and neoplasm: Treatment of SDHA-KO B6 animals with anti-PD-1 demonstrated similar tumor control to isotype control antibody-treated KO animals, demonstrating that deficiency of SDHA enhanced CD8+ T cell–mediated antitumor immunity to a similar degree as the treatment with anti-PD1 therapy.